Clinical and molecular comparison between borderline serous ovarian tumors and advanced serous papillary ovanan carcinomas

The aim of this study was to characterize the clinical and molecular markers of borderline serous ovarian tumors (BSOT), and to study their expression in the progression from benign lesions to advanced serous papillary ovarian carcinomas (SPOC). The clinical records of 20 patients with BSOT and 22 patients with SPOC were reviewed. Specimens from all these cases and from six benign ovarian serous cystadenomas were evaluated for expression of estrogen receptors (ER), progesterone receptors (PR), p53. HER-2/neu and Ki-67 by immunohistochemical techniques. The mean patient age and the age at menarche differed significantly between the compared groups of BSOT and SPOC (p=0.0006 and p=0.0014, respectively). No difference was observed comparing the other clinical parameters. The immunohistochemical analysis demonstrated a significant increase in the expression of ER (100% vs 72.7%), and a significant decrease in the immunoreactivity for p53 (0% vs 45.4%) and Ki-67 (2% vs 26.8%) in cases of BSOT compared with those of SPOC (p=0.007, p=0.0003 and p=0.012, respectively). No significant difference was demonstrated comparing the expression of PR and HER-2/neu. The immunostaining of benign ovarian serous cystadenoma specimens did not differ significantly from immunoreactivity observed in cases of BSOT. According to immunohistochemical analysis, BSOT had much more in common with benign serous tumors than with SPOC. The main difference between BSOT and SPOC was regarding the overexpression of p53 and Ki-67.

Borderline serous ovarian tumor; Serous papillary ovarian carcinoma; Benign serous ovarian tumor; Immunohistochemistry; Clinical parameters; Molecular markers

[1] Powell D. E., Puls L., Van Nagell J.: "Current concepts in epithe-lial tumours: Does benign to malignant transformation occur?". Human. Pathol., 1992, 23, 846.

[2] Russell P.: "Borderline epitbelial tumours of the ovary: a conceptual dilemma". Clin. Ohstet. Gynecol., 1984, 11, 259.

[3] Leake J. F.: "Tumors of low malignant potential". Curr. Optn Obstet. Gynecol., 1992, 4, 81.

[4] Kacinski B.M .,M ayer A.G., King B. L.,C arter D.,C hambers S. K.: "NEU protein overexpression in benign, borderline, and malignant ovarian neoplasms". Gynecol. Oneal., 1992, 44, 245.

[5] Wang D., Kanish I.. Koshiyama M., Nabu Y., Iwai T., Nonogaki H.,M ori T., Fuju S.: "Immunohistochemical localization of cerbB-2 protein and epidermal growth factor receptor in normal surface epithelium,s urface inclusion cysts， and common epithelial tumours of the ovary". Virchows. Archiv. A. Pathol. Anal., 1992, 421, 393.

[6] Klemi P. J., Takashi S., Joensuu H., Kiilhoma P., Narimatsu E., Mori M.:''Immunohistochemical detection of p53 protein in borderline and malignant serous ovarian tumors“ Int. J. Gynecol Pathol., 1994, 13, 228.

[7] Kiyokawa T.: "Alteration of p53 in ovarian cancer: Its occurrence and maintenance in tumor progression". Int. J. Gynecol. Pathol., 1994,13,311.

[8] Berchuck A., Kohler M. F., Hopkins M. P., Humphrey P. A., Robboy S. J.. Rodriguez G. C., Soper J. T., Clarke-Pearson D. L., Bast R. C.: "Overexpression of p53 is not a feature of benign and early-stage borderI ine epithelial ovarian tumors". Gynecol Oneal., 1994, 52, 232.

[9] Wertheim I.,M uto M. G., Welch W. R., Bell D. A.,B erkowitz R S.,M ok S. C.: "p53 Gene mutation in human borderline epithelial ovarian tumors". J. Natl. Cancer Inst., 1994, 86, 1549.

[10] Kupryianczyk J., Bell D. A., Yandell D. W., Scully R. E., Thor A. D.: "p53 expression in ovarian borderline tumors and stage I carcinomas". Am. J. Clin. Pathol., 1994, 102, 671.

[11] Lee J. H., Kang Y. S., Park S. Y., Kim B. G., Lee E. D., Lee K. H et al.: "p53 mutation in epithelial ovarian carcinoma and borderline ovarian tumor". Cancer Genet. Cytogenet., 1995, 85, 43.

[12] Van Haaften-Day C., Russell P., Boyer C. M., Kerns B. J.M., Wiener J. R., Jensen D. W. et al.: "Expression of cell regulatory proteins in ovarian borderline tumors". Cancer, 1996, 77, 2092.

[13] Eltabbahk G. H., Belinson J. L., Kennedy A. W., Biscotti C. V., Casey G., Tubbs R. R.: "p53 and HER-2/neu overexpression in ovarian borderline tumors". Gynecol. Oncol., 1997, 65, 218.

[14] Cancer Committee of the International Federation of Gynecology and Obstetrics: "Staging Announcement FIGO Cancer Committee". Gynecol. Oncol., 1986, 25, 383.

[15] Cheng W., Cao P., Zheng M., Kramer E. E., Godwin T.A.: "p53 overexpression and bcl-2 persistence in endometrial carcinoma: comparison of papillary serous and endometrioid subtypes". Gynecol. Oncol., 1996, 61, 167.

[16] Koshiyama M., Konishi I., Mandai M., Komatsu T., Yamamoto S., Nbanbu K., Mori T.: "Immunohistochemical analysis of p53 protein and 72 kDa heat shock protein (HSP72) expression in ovarian carcinomas. Correlation with clinicopathology and sex steroid receptor status". Virchows Archiv., 1995, 425, 603.

[17] Marcelli A. R., Demopoulos R. I., Goswani S., Mittal K. R.: "Comparison of p53 and MIBI expression in benign and borderline areas of serous tumors". Int. J. Gynecol. Pathol., 1996, 15, 39.

[18] Seidman J. D., Frisman D. M., Norris H.J.: "Expression of HER-2/neu protooncogene in serous ovarian neoplasms". Cancer, 1990, 70, 2857.

[19] Kacinski B. M., Mayer A.G., King B. L., Carter D., Chambers S. K.: "NEU protein overexpression in benign, borderline, and malignant ovarian neoplasms". Gynecol. Oncol., 1992, 44, 245.

[20] Singleton T. P., Perrone T., Oakley G., Niehans G. A., Carson L., Cha S. S., Strickler J. G.: "Activation of c-erbB02 and prognosis in ovarian carcinoma: comparison with histologic type, grade and stage". Cancer, 1994, 73, 1460.

[21] Felip E., Camo J. M. D., Rubio D., Vidal M. T., Colomer R., Bermejo B.: "Overexpression of c-erbB-2 in epithelial ovarian cancer". Cancer, 1995, 75, 2147.

[22] Rubin S. C., Finstad C. L., Federici B. S., Scheiner L., Lloyd K.O., Hoskins W. J.: "Prevalence and significance of HER-2/neu expression in early epithelial ovarian cancer". Cancer, 1994, 73, 1456.

[23] Guterson B. A., Gelber R. D., Goldhirsch A., Price K. N., SaveSoder-Borgh J., Anbazhagan R. et al.: "Prognostic importance of c-erbB-2 expression in breast cancer". J. Clin. Oncol., 1992, 10, 1049.

[24] Gerdes J., Schwab U., Lemke H., Stein H.: "Production of mouse monoclonal antibody reacting with a human nuclear antigen associated with proliferation". Int. J. Cancer, 1983, 31, 13.

[25] Isola J., Kallioniemi 0. P., Korte J. M., Wahlstrom T., Aine R., Helle M., Helin H.: "Steroid receptors and Ki 67 reactivity in ovarian cancer and in normal ovary: correlation with DNA flow cytometry, biochemical receptor assay, and patient survival". J. Pathol., 1990, 162, 295.

[26] Darai E., Walker-Combrouze F., Dauge-Geoffroy M. C., Vincent Y., Feldmann G., Madelenat P., Scoazec J. Y.: "Ki 67 expression in 35 borderline ovarian tumors: relations with clinicopathologic parameters and ploidy". Eur. J. Obstet. Gynecol., 1996, 66, 141.

[27] Powell D. E., Puls L., Van Nagell J.: "Current concepts in epithelial tumours: Does benign to malignant transformation occur?". Human. Pathol., 1992, 23, 846.

[28] van Haaften-Day C., Russel P., Davies S., Bramrnah-Carr S.: "An in vitro study of ovarian atypical proliferating (borderline) serous tumors". Int. J. Gynecol. Cancer, 1992, 2, 41.